328038-28-4 Usage
Description
4-[BIS-(2-METHOXY-ETHYL)-SULFAMOYL]-BENZOIC ACID, also known as 4-(N,N-bis(2-Methoxyethyl)sulfamoyl)benzoic acid, is an organic compound with a unique chemical structure that features a benzoic acid core and two sulfamoyl groups attached to it. 4-[BIS-(2-METHOXY-ETHYL)-SULFAMOYL]-BENZOIC ACID is characterized by its potential applications in various fields, particularly in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
4-[BIS-(2-METHOXY-ETHYL)-SULFAMOYL]-BENZOIC ACID is used as a reactant for the discovery and initial development of a novel class of antibacterials. Specifically, it serves as a key component in the creation of inhibitors targeting Staphylococcus aureus transcription/translation processes. By disrupting the bacterial cell's ability to transcribe and translate genetic information, this compound can effectively combat the growth and spread of harmful bacteria, particularly those resistant to conventional antibiotics.
Check Digit Verification of cas no
The CAS Registry Mumber 328038-28-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,8,0,3 and 8 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 328038-28:
(8*3)+(7*2)+(6*8)+(5*0)+(4*3)+(3*8)+(2*2)+(1*8)=134
134 % 10 = 4
So 328038-28-4 is a valid CAS Registry Number.
328038-28-4Relevant articles and documents
Discovery and initial development of a novel class of antibacterials: Inhibitors of Staphylococcus aureus transcription/translation
Larsen, Scott D.,Hester, Matthew R.,Craig Ruble,Kamilar, Gregg M.,Romero, Donna L.,Wakefield, Brian,Melchior, Earline P.,Sweeney, Michael T.,Marotti, Keith R.
, p. 6173 - 6177 (2007/10/03)
The novel bacterial transcription/translation (TT) inhibitor 1 was identified through a combination of high throughput screening and exploratory medicinal chemistry. Initial optimization of the anthranilic acid moiety and sulfonamide amine diversity was accomplished via 1- and two-dimensional solution phase libraries, resulting in an improvement in the MIC of the lead from 64 to 8 μg/mL (compound 4l). Subsequent modification of the central aromatic ring and further refinement of the sulfonamide amines required the development of a solid phase route on Wang resin. The resulting libraries generated a number of potent antibacterials with MICs of ≤1 μg/mL (e.g., 10b, 12, and 13). During the course of this work, it became apparent that the antibacterial activity of the series is not fully correlated with TT inhibition, suggesting that at least one additional mechanism of action is operative.
